Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lower dose vs standard dose atazanavir/ritonavir in HIV-infected adults
NCT01159223Phase 4Completed
- Sponsor
- HIV-NAT
- Start
- May 2011
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of atazanavir in human immunodeficiency virus infection (HIV), sponsored by HIV-NAT. Primary endpoint: Proportion of virologic responders at 48 weeks. Started May 2011; status: completed.
02
Drugs
atazanavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT01159223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01159223.